| Bid price | 78.00 | Open price | 78.00 |
|---|---|---|---|
| Ask price | 79.00 | Prev close | 78.50 |
| High price | 80.95 | Spread | 1.27% |
| Low price | 76.50 | Volume | 133,843 |
Register now for FREE live ImmuPharma share prices, ImmuPharma stock quotes, charts, trades and FREE ImmuPharma company fundamentals, market news and much much more. Why not upgrade to a premium service and get ImmuPharma Level 2 Data, indepth research tools and investor commentary for ImmuPharma (IMM) and other London Stock Exchange equities.
Register now for FREE ImmuPharma share price charts
| Name | ImmuPharma | Epic | IMM |
|---|---|---|---|
| Activites | Invests in pharmaceutical research and development companies | Reuters | IMM.L |
| ISIN | GB0033711010 | Google Finance | LON:IMM |
| Share Price (p) | 78.50 | Prev. Share Price (p) | 78.50 |
|---|---|---|---|
| Shares in Issue (m) | 82 | Market Cap (£m) | 64 |
| PE Ratio (x) | -35.66 | Div per share (p) | 0.00 |
| Div yield (%) | 0.00 | Div cover (x) | |
| EPS (p) | -2.40 | PEG |
Register now for FREE ImmuPharma company fundamentals
| Dec.Date | Type | Director | Pos | No. of Shares |
|---|---|---|---|---|
| 24/01/2012 | BUY | Dr Franco Di Muzio | NED | 60,950 |
| 24/01/2012 | BUY | Dr Ajay Agrawal | NED | 62,169 |
| 23/07/2009 | SELL | Richard Warr | CH | 6,250,000 |
| 23/07/2009 | SELL | Dimitri Dimitriou | CEO | 6,250,000 |
Dr Ajay Agrawal, Non Executive Director, bought 62,169 shares in the company on the 24th January 2012 at a price of 80.00p. The Director now holds 62,169 shares. Story provided by StockMarketWire.com Director deals data provided by www.directorsholdings.com
Dr Franco Di Muzio, Non Executive Director, bought 60,950 shares in the company on the 23rd January 2012 at a price of 81.00p. The Director now holds 60,950 shares. Story provided by StockMarketWire.com Director deals data provided by www.directorsholdings.com
/* */ RNS Number : 0860W Immupharma PLC 24 January 2012 IMMUPHARMA...
More ImmuPharma Company News >>
Register now for FREE ImmuPharma company news
From today's Times: Tiddler to watch "ImmuPharma, steady at 46p, the biotech group which has a treatment of the disease Lupus in phase II trials, could benefit from the failure this week of trials of rival drug Rituxan. ImmuPharma's housebroker, Panmure Gordon, believes its client may...
Register now for FREE ImmuPharma share price discussions